Abstract
Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine.
Cite
CITATION STYLE
Brito, S., Ferreira, N., Mateus, S., Bernardo, M., Pinto, B., Lourenço, A., & Grenho, F. (2021). A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination. Cureus. https://doi.org/10.7759/cureus.15035
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.